MaxCyte Inc
Change company Symbol lookup
Select an option...
MXCT MaxCyte Inc
WDAY Workday Inc
BNOX Bionomics Ltd
NRDY Nerdy Inc
KEY KeyCorp
AMPX Amprius Technologies Inc
TPC Tutor Perini Corp
LTRN Lantern Pharma Inc
JGGC Jaguar Global Growth Corporation I
WHG Westwood Holdings Group Inc
Go

Health Care : Life Sciences Tools & Services | Small Cap Growth
Company profile

MaxCyte, Inc. is a commercial cell engineering company. The Company is focused on providing enabling platform technologies to advance cell-based research and development, as well as next-generation cell therapeutic discovery, development and commercialization. The Company has developed and commercialized its Flow Electroporation platform, which facilitates complex engineering of a variety of cells. Its ExPERT platform is based on its Flow Electroporation technology, which has been designed to address the cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. Its ExPERT platform consists of three instruments, which are known as the ATx, STx, GTx and VLx. Its ATx static electroporation instrument is research focused, performance electroporation platform for small to medium scale transfection. Its STx is used in the field of protein production.

Closing Price
$3.17
Day's Change
0.09 (2.92%)
Bid
--
Ask
--
B/A Size
--
Day's High
3.22
Day's Low
3.01
Volume
(Heavy Day)
Volume:
905,474

10-day average volume:
720,843
905,474

Unable to locate that news article. Back to news results

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.